ClearBridge Investments
ESPR

ClearBridge Investments’s Esperion Therapeutics ESPR Stock Holding History

ClearBridge Investments’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$5K – 1198
2017
Q2 		$5K Buy
+100
New +$3.68K ﹤0.01% 1137

Other funds holding ESPR

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

ClearBridge Investments's ESPR Position: Q3 2017 in Review

ClearBridge Investments sold out of Esperion Therapeutics (ESPR) in Q3 2017, closing a stake of 100 shares — an estimated $5K sold.

ClearBridge Investments first reported a position in ESPR in Q2 2017 and held it in 1 quarter. The position peaked at $5K in Q2 2017. 150 funds tracked by Wall St. Rank hold ESPR as of Q3 2017.

  • ClearBridge Investments reported no remaining Esperion Therapeutics position as of Q3 2017 after selling out during the quarter.
  • ClearBridge Investments sold 100 Esperion Therapeutics shares in Q3 2017, an estimated $5K.
  • ClearBridge Investments first reported a position in Esperion Therapeutics in Q2 2017 and held it in 1 quarter.
  • ClearBridge Investments's Esperion Therapeutics position peaked at $5K in Q2 2017.
  • 150 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2017.

Based on ClearBridge Investments's 13F filing for Q3 2017, filed 14 Nov 2017.